Intrinsiqq
Coherus Biosciences Inc. logo

Coherus Biosciences Inc.

CHRS

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$81M
EPS-$1.00
P/E-0.53
P/FCF–
EV/EBITDA0.00
FCF Yield–
Div. Yield–
Net Debt/FCF–
Coherus Biosciences Inc. intrinsic value
52-Week Range
$0.53$1.58

Profitability & Returns

Revenue (TTM)

$54M

▲ +59.8% YoY

Net Income (TTM)

-$136M

▲ +489.4% YoY

Op. Margin

-275.94%

▲ +327.1pp YoY

ROIC

-200.43%

▲ +2120.6pp YoY

Cash Flow & Balance Sheet

FCF (FY)

-$609M

▼ -145.2% YoY

Op. Cash Flow (TTM)

-$174M

▼ -577.7% YoY

Net Debt

-$82M

Net Cash Position

Cash & Equiv.

$84M

5Y CAGR: -38.4%

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CHRS

CompareIntrinsic value
EDITEditas Medicine Inc.
$2.17+1.40%40
IVVDInvivyd Inc.
$0.58+2.65%10
FENCFennec Pharmaceuticals Inc.
$11.62+6.61%50
CSBRChampions Oncology, Inc.
$4.71+1.29%26
STROSutro Biopharma, Inc.
$9.82+2.40%10
DTILPrecision Biosciences Inc.
$7.57-5.91%48
PTHSPelthos Therapeutics Inc.
$7.44-7.35%0
RXRXRecursion Pharmaceuticals, Inc.
$3.19-4.35%25

Held by ETFs

CHRS is in 4 US ETFs. The largest of them, with CHRS's weight in each:

Coherus Biosciences (CHRS) in four numbers

Fair value (revenue)
$0.62
Price $0.53 is 16% below it.
Intrinsic Value
Quality score
10/100
Best check: net debt, -$82M. Weakest: return on capital, -200.4%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-0.53
Negative: a loss over the last twelve months.
Financials

Questions about Coherus Biosciences

Is Coherus Biosciences (CHRS) overvalued?

At $0.53, Coherus Biosciences' price is 16% below the $0.62 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Coherus Biosciences' fair value?

Intrinsiqq's calculator puts Coherus Biosciences' fair value at $0.62 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 2.9, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.47. Every input can be changed on the Intrinsic Value tab.

Is Coherus Biosciences a high-quality business?

Coherus Biosciences scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$82M, and its weakest is return on capital at -200.4%. The Quality tab shows every check against its target.

Does Coherus Biosciences (CHRS) pay a dividend?

No. Coherus Biosciences (CHRS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 31 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 13 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in CHRS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CHRS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.